Teprotumumab-trbw (Tepezza)





PATIENT INFORMATION	Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal
Patient Name:	DOB: Patient Phone:
Patient Address:	Patient Email:
Allergies:	☐ NKDA Weight (lbs/kg): Height (in/cm):
Sex: ☐ M / ☐ F Date of Last Infusion:	Next Due Date: Preferred Location:
DIAGNOSIS (Please provide ICD-10 code in space	e provided)
-	0: Thyrotoxicosis with diffuse goiter
Other: Descrip	
THERAPY ADMINISTRATION & DOSING	MONITORING & MANAGEMENT
 ☑ Administer Teprotumumab-trbw (Tepezza) intrave 0.9% sodium chloride: First infusion: 10 mg/kg IV x (current wein kg = mg x 1 dose) Subsequent (Infusions 2-8): 20mg/kg IV x (weight) kg = mg x 7 ☑ Doses up to 1800mg mix in NS to final volume of 2 greater than 1800mg, mix in NS 250ml ☑ Infuse over 90 mins for the first 2 doses. If patient well, all future infusions can infuse over 60mins FREQUENCY (Choose one) □ Every 3 weeks (8 infusions total) □ Every weeks LABORATORY ORDERS □ CBC □ at each dose □ every: □ cmp 	Hold infusion and notify provider for:
□ Other: PRE-MEDICATION ORDERS □ Loratadine 10mg PO □ Tylenol □500mg / □650mg PO □ Solumedrol □ 40mg/ □ 125mg IVP □ Benadryl □ 25 mg / □ 50mg □ PO / □ IV □ Other:	 Hearing Assessment and Baseline Audiogram Has patient completed baseline audiogram: ☐ Yes (include results) ☐ No ■ Baseline and follow up audiograms WILL NOT be completed by Novella Infusion (Recommended that all patients receive baseline audiogram prior to 1st infusion with follow up testing at 12 wks, 24 wks and 6 mos.) ☑ Hearing questionnaire performed by Novella Infusion prior to infusion
PROVIDER INFORMATION	
Preferred Contact Name:	Preferred Contact Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
Required Documentation: Patient demos, copy of treatment failures or contraindications, include in	Additional documentation required for processing and insurance approval) front and back of primary and secondary insurance, 2 most recent OVN including history (please reference specific payor policy guidelines): Lid retraction in mm, opia, eye pain, proptosis, history of steroid use and CAS scores free T3 and T4 levels)
	rovider Signature Date Date Discreption of the state o

Disclaimer: By signing this form, I authorize Novella Infusion and its affiliates to act as my designated agent in submitting prior authorizations, financial assistance applications, and other clinically required information with respect to this patient and order. This enrollment form shall serve as my signature for prior authorizations and financial assistance programs, as requested.